| Symbol | DMAC |
|---|---|
| Name | DIAMEDICA THERAPEUTICS INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | TWO CARLSON PARKWAY,SUITE 260, MINNEAPOLIS, Minnesota, 55447, United States |
| Telephone | +1 763 612-6755 |
| Fax | — |
| — | |
| Website | https://www.diamedica.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001401040 |
| Description | DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1. Additional info from NASDAQ: |
(30% Negative) DIAMEDICA THERAPEUTICS INC. (DMAC) Reports Q2 2026 Financial Results
Read morePress Release: DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
Read moreDiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
Read morePress Release: DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026
Read moreDiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026
Read moreNew Form ARS - DiaMedica Therapeutics Inc. <b>Filed:</b> 2026-04-01 <b>AccNo:</b> 0001437749-26-010881 <b>Size:</b> 11 MB
Read moreNew Form DEF 14A - DiaMedica Therapeutics Inc. <b>Filed:</b> 2026-04-01 <b>AccNo:</b> 0001437749-26-010879 <b>Size:</b> 4 MB
Read morePress Release: DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights
Read moreDiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights
Read morePress Release: DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06875141 | DM199 for Pregnancy Complications | Na | Pre-Eclampsia | Withdrawn | 2025-05-01 | 2025-05-01 | ClinicalTrials.gov |
| NCT05065216 | Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) | Phase2 | Acute Stroke | Recruiting | 2021-11-07 | 2026-12-01 | ClinicalTrials.gov |
| NCT04123613 | Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX) | Phase2 | Kidney Diseases | Completed | 2019-12-17 | 2022-03-16 | ClinicalTrials.gov |
| NCT03795389 | Study to Assess PK, Safety and Tolerability in Patients With DM and CKD | Phase1 | Chronic Kidney Disease | Completed | 2019-02-12 | 2019-07-21 | ClinicalTrials.gov |
| NCT03290560 | Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Is… | Phase2 | Acute Ischemic Stroke | Completed | 2018-01-19 | 2020-01-23 | ClinicalTrials.gov |
| NCT02868996 | An Open Label, Phase 1b, Ascending Dose Study of DM199 | Phase1 | Stroke | Completed | 2016-09-01 | 2017-03-01 | ClinicalTrials.gov |
| NCT01845064 | A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects a… | Phase1 | Diabetes Type 2 | Completed | 2013-04-01 | 2014-11-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE1 | Diabetes Type 2 | COMPLETED | NCT01845064 |
| DM199 | Other | Phase PHASE1 | Diabetes Type 2 | COMPLETED | NCT01845064 |
| Recombinant human tissue kallikrein | Other | Phase PHASE1 | Stroke | COMPLETED | NCT02868996 |
| DM199 | Other | Phase PHASE1 | Chronic Kidney Disease | COMPLETED | NCT03795389 |
| DM199 | Other | Phase PHASE2 | Kidney Diseases | COMPLETED | NCT04123613 |
| Placebo | Other | Phase PHASE2 | Acute Ischemic Stroke | COMPLETED | NCT03290560 |
| Recombinant human tissue kallikrein | Other | Phase PHASE2 | Acute Ischemic Stroke | COMPLETED | NCT03290560 |
| DM199 | Other | Approved | Pre-Eclampsia | WITHDRAWN | NCT06875141 |
| Placebo for DM199 Solution for Injection | Other | Phase PHASE2 | Acute Stroke | RECRUITING | NCT05065216 |
| Recombinant human tissue kallikrein | Other | Phase PHASE2 | Acute Stroke | RECRUITING | NCT05065216 |
| Placebo for DM199 Solution for Injection | Other | Phase PHASE2 | Acute Stroke | RECRUITING | NCT05065216 |
| Recombinant human tissue kallikrein | Other | Phase PHASE2 | Acute Stroke | RECRUITING | NCT05065216 |
| Placebo for DM199 Solution for Injection | Other | Phase PHASE2 | Acute Stroke | RECRUITING | NCT05065216 |
| Recombinant human tissue kallikrein | Other | Phase PHASE2 | Acute Stroke | RECRUITING | NCT05065216 |
| Placebo for DM199 Solution for Injection | Other | Phase PHASE2 | Acute Stroke | RECRUITING | NCT05065216 |
| Recombinant human tissue kallikrein | Other | Phase PHASE2 | Acute Stroke | RECRUITING | NCT05065216 |
| Placebo for DM199 Solution for Injection | Other | Phase PHASE2 | Acute Stroke | RECRUITING | NCT05065216 |
| Recombinant human tissue kallikrein | Other | Phase PHASE2 | Acute Stroke | RECRUITING | NCT05065216 |
| Placebo for DM199 Solution for Injection | Other | Phase PHASE2 | Acute Stroke | RECRUITING | NCT05065216 |
| Recombinant human tissue kallikrein | Other | Phase PHASE2 | Acute Stroke | RECRUITING | NCT05065216 |
| Placebo for DM199 Solution for Injection | Other | Phase PHASE2 | Acute Stroke | RECRUITING | NCT05065216 |
| Recombinant human tissue kallikrein | Other | Phase PHASE2 | Acute Stroke | RECRUITING | NCT05065216 |
| Placebo for DM199 Solution for Injection | Other | Phase PHASE2 | Acute Stroke | RECRUITING | NCT05065216 |
| Recombinant human tissue kallikrein | Other | Phase PHASE2 | Acute Stroke | RECRUITING | NCT05065216 |
| Placebo for DM199 Solution for Injection | Other | Phase PHASE2 | Acute Stroke | RECRUITING | NCT05065216 |
| Recombinant human tissue kallikrein | Other | Phase PHASE2 | Acute Stroke | RECRUITING | NCT05065216 |
| Placebo for DM199 Solution for Injection | Other | Phase PHASE2 | Acute Stroke | RECRUITING | NCT05065216 |
| Recombinant human tissue kallikrein | Other | Phase PHASE2 | Acute Stroke | RECRUITING | NCT05065216 |
| Placebo for DM199 Solution for Injection | OTHER | Phase PHASE2 | Acute Stroke | RECRUITING | NCT05065216 |
| Recombinant human tissue kallikrein | DRUG | Phase PHASE2 | Acute Stroke | RECRUITING | NCT05065216 |
| Placebo | OTHER | Phase PHASE2 | Acute Ischemic Stroke | COMPLETED | NCT03290560 |
| DM199 | BIOLOGICAL | Approved | Pre-Eclampsia | WITHDRAWN | NCT06875141 |